Study design (if review, criteria of inclusion for studies)
Post hoc analyses of pooled phase 3 data (NCT01807923, NCT01807949)
Participants
Patients with cystic fibrosis homozygous for F508del.
Interventions
lumacaftor/ivacaftor (LUM/IVA)
Outcome measures
Pulmonary exacerbations (PEx)
Main results
LUM (400mg q12h)/IVA (250mg q12h)-treated patients (n=369) experienced significantly fewer PEx vs placebo, regardless of threshold category. With LUM/IVA, PEx rate per patient per year was 0.60 for those with absolute change in ppFEV1>0 and 0.85 for those with absolute change =0 (respective rate ratios vs placebo [95% CI]: 0.53 [0.40-0.69; P<.0001], 0.74 [0.55-0.99; P=.04]).
Authors' conclusions
LUM/IVA significantly reduced PEx, even in patients without early lung function improvement.